Haemonetics Corp: (NYSE: HAE)

$42.31

0.50 (1.20%)

Volume 331,113

May 22 12:56 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		41.80 - 42.48
	
		52wk Low - High
		32.69 - 44.44
	
		Previous Close
		41.81
	
		Avg. Volume
		430,983
	
		Industry
		MED PRODUCTS
	
		Market Cap
		2.16 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.42
	
		PE (Forward)
		19.27
	
		Current Year Est.
		2.17
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		177 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/11/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            19.27
                        
                            PEG Ratio
                            1.56
                        
                            Current Year Est.
                            2.17
                        
                            Current Quarter Estimate
                            0.43
                        
                            Most Accurate Estimate
                            0.43
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            1.71
                        
                            Expected Earnings Growth
                            12.33%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections.  The majority of their business is outside the US.   
Full HAE Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
HAE Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (03/2014)	Next Year (03/2015)
Average Estimate	0.43	0.53	2.17	2.64
Number of Estimates	5	5	5	3
Low Estimate	0.36	0.45	1.89	2.55
High Estimate	0.47	0.58	2.34	NA
Year Ago EPS	0.28	0.45	1.71	2.17
EPS Growth	56.36%	17.33%	26.90%	21.81%

More HAE Estimates

Average Earnings Estimates for HAE

EPS Growth for HAE

Industry Analysis

Name	Symbol	Previous Close
HAEMONETICS CP	HAE	41.81
CONCEPTUS INC	CPTS	30.98
ATRICURE INC	ATRC	8.99
INVIVO THERAPT	NVIV	2.90
TRANS1 INC	TSON	1.59
ABAXIS INC	ABAX	44.22
ADVAXIS INC	ADXS	0.05
BAXTER INTL	BAX	73.04
BIO-RAD LABS -A	BIO	116.12
BIOLIFE SOL INC	BLFS	0.38

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

HAE Beats on Earnings, Revs in Line

May 03, 2013

Haemonetics Closes Hemerus Acquisition

May 02, 2013

Covidien Likely to Beat Earnings?

Apr 24, 2013

Will Stryker Miss Earnings this Quarter?

Apr 23, 2013

Will CR Bard Miss Earnings this Quarter?

Apr 22, 2013

Haemonetics Back to Neutral

Apr 15, 2013

Palls New Center of Excellence

Apr 05, 2013

PLL Expands into Research

Mar 06, 2013

More HAE Zacks Commentary

Financials

EPS TTM	1.71
Sales	892
Net Income	39
Price/Earnings	24.52
Price/Book	2.81
Price/Cash Flow	13.83
Price/Sales	2.42

More HAE Financials

News

Apheresis Market by Applications, Devices & Disposables with Forecasts To 2017 - Haemonetics Corporation leads the market - M2

May 22, 2013

Research and Markets: Apheresis Market by Applications, Devices & Disposables with Forecasts To 2017 - Haemonetics Corporation leads the market - Businesswire

May 22, 2013

Top 5 Companies in the Health Care Supplies Industry with the Best Relative Performance (HAE, ELGX, ALGN, CERS, XRAY) - Financial News Network Online - News Corner

May 22, 2013

Haemonetics Makes a Move: Up 1.5% - Financial News Network Online - Market Movers

May 16, 2013

Quidel Ranks the Highest in Terms of EBITDA Growth in the Health Care Supplies Industry (QDEL, HAE, RTIX) - Financial News Network Online - News Corner

May 14, 2013

Haemonetics reports lower Q4 net income, provides outlook for fiscal 2014 - Datamonitor

May 10, 2013

Haemonetics Fulfills the Promise: Up 1.8% Since Last Week's Upgrade - Financial News Network Online - News Corner

May 9, 2013

Analyst Rating In Review: Haemonetics Sold Off 2.2% Since Upgraded 7 Days Ago (HAE) - Financial News Network Online - News Corner

May 3, 2013

See All News Stories on HAE

Broker Recommendations

Current ABR	2.00
ABR (Last Week)	2.20
# of recs in ABR	6
Average Target Price	44.50
Industry Rank by ABR	177 out of 265
Rank in Industry	5 out of 73

More HAE Broker Recommendations

Day Low - High	41.80 - 42.48
52wk Low - High	32.69 - 44.44
Previous Close	41.81
Avg. Volume	430,983
Industry	MED PRODUCTS
Market Cap	2.16 B
Div - Yield	0.00 - 0.00
Beta	0.42
PE (Forward)	19.27
Current Year Est.	2.17
Quarterly Earnings ESP	0.00%

PE (Forward)	19.27
PEG Ratio	1.56
Current Year Est.	2.17
Current Quarter Estimate	0.43
Most Accurate Estimate	0.43
Earnings ESP	0.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	1.71
Expected Earnings Growth	12.33%

Username: Password:

Remember me [?]

Haemonetics Corp: (NYSE: HAE)

$42.31

0.50 (1.20%)

Volume 331,113

May 22 12:56 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED PRODUCTS

Zacks Commentary

Financials

News

Broker Recommendations